Trial Condition(s):

Carcinoma, Hepatocellular

GIDEON Non-Nexavar Arm - HCC patients who are treated with any therapy other than Nexavar at individual study start

Bayer Identifier:

14611

ClinicalTrials.gov Identifier:

NCT01191385

EudraCT Number:

Not Available

Terminated/Withdrawn

Trial Purpose

This study is an international prospective, open-label, multi-center, non-interventional study. The protocol will allow enrollment of all patients with diagnosis of HCC in whom a decision to treat with sorafenib has not been made at time of study enrollment. All patients will be followed-up until withdrawal of consent, lost to follow-up, death, or the end of the study. Detailed information concerning the past medical/surgical history, performance status, methods of diagnosis and staging, etc. of patients with HCC will be collected, and practice patterns of the physicians involved in the care of patients with HCC under real-life conditions will be evaluated.

Inclusion Criteria
- Outpatients with histologically/cytologically documented or radiographically diagnosed HCC in whom a decision to treat with sorafenib has not been made at this time. Radiographic diagnosis needs typical findings of HCC by radiographic method i.e. on multi-dimensional dynamic CT, CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or MRI. 
 - Patients must have signed an informed consent form
 - Patients must have a life expectancy of at least 8 weeks
Exclusion Criteria
-  Patients in whom a decision to treat with sorafenib is made at time of study start
 - Patients who have received sorafenib in the past or are currently treated with sorafenib  
 - Hospice patients

Trial Summary

Enrollment Goal
0
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 
Locations

Investigative Site

Many Locations, United States

Status
Terminated
 

Trial Design